Valuation: SELLAS Life Sciences Group, Inc.

Market Cap 1.73B 1.54B 1.42B 1.29B 2.42B 164B 2.48B 16.91B 6.8B 86.33B 6.48B 6.34B 274B P/E 2026 *
-41.7x
P/E 2027 * -90x
Enterprise Value 1.73B 1.54B 1.42B 1.29B 2.42B 164B 2.48B 16.91B 6.8B 86.33B 6.48B 6.34B 274B EV / Sales 2026 *
-
EV / Sales 2027 * 32.5x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SELLAS Life Sciences Group, Inc.

1 day+2.75%
1 week-27.73%
Current month-9.14%
1 month-24.38%
3 months-21.61%
6 months+75.20%
Current year+133.29%
1 week 8.48
Extreme 8.4801
12.44
1 month 8.48
Extreme 8.4801
12.7
Current year 3.23
Extreme 3.23
15.88
1 year 1.39
Extreme 1.39
15.88
3 years 0.5
Extreme 0.4986
15.88
5 years 0.5
Extreme 0.4986
15.88
10 years 0.5
Extreme 0.4986
554.5
Manager TitleAgeSince
Chief Executive Officer 50 29/12/2017
Director of Finance/CFO 41 30/12/2017
Compliance Officer - -
Director TitleAgeSince
Director/Board Member 50 29/12/2017
Chairman 66 01/06/2024
Director/Board Member 69 29/12/2017
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/26 Free

Executive/Senior Manager

300,000 0.2106%
7/1/26 Free

Director

50,000 0.0351%
7/1/26 Free

Chief Financial Officer

300,000 0.2106%
Change 5-day change 1-year change 3-year change Capi.($)
+3.04%-27.73%+391.34%+816.15% 1.73B
-2.43%-7.34%+36.10%+58.44% 62.23B
+0.61%+0.77%+11.13%+69.42% 54.92B
+0.62%+2.58%+20.96%+98.18% 55.26B
+1.26%-3.55%+22.46%+32.82% 42.59B
-1.47%-3.10%+13.69%+92.92% 41.08B
+3.73%+4.29%+227.32%+776.35% 40.33B
+0.57%+24.09%+99.46%+84.11% 33.12B
-1.09%-0.05%+13.55%+45.35% 32.61B
-3.98%+10.30%-43.76%+321.49% 23.98B
Average +0.06%+0.91%+79.22%+239.52% 38.78B
Weighted average by Cap. -0.11%+1.99%+46.58%+161.88%

Financials

2026 *2027 *
Net sales - 53.09M 47.43M 43.57M 39.57M 74.31M 5.03B 76.18M 520M 209M 2.65B 199M 195M 8.41B
Net income -38.3M -34.21M -31.43M -28.54M -53.6M -3.63B -54.95M -375M -151M -1.91B -144M -141M -6.07B -21.38M -19.1M -17.54M -15.93M -29.92M -2.02B -30.67M -209M -84.24M -1.07B -80.24M -78.52M -3.39B
Net Debt - -
Projected Income Statement - Annual - SELLAS Life Sciences Group, Inc.
Logo SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Employees
-
Date Price Change Volume
04/11/26 USD 8.800 +2.92% 3,717,618
02/11/26 USD 8.550 -11.67% 14,417,625
30/10/26 USD 9.680 -4.68% 6,261,984
29/10/26 USD 10.16 -2.17% 8,357,644
28/10/26 USD 10.38 -14.71% 23,771,723
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - SELLAS Life Sciences Group, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.550USD
Average target price
32.50USD
Spread / Average Target
+280.12%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - SELLAS Life Sciences Group, Inc.